SCHEMBL28565628

SCHEMBL28565628

Cc1ccc(S(=O)(=O)N/N=C2/CCN(C(=O)OCc3ccccc3)C2)cc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.60
HPN P05981 1/20 0.47
ST14 Q9Y5Y6 1/20 0.47
CA1 P00915 5/20 0.46
CA2 P00918 5/20 0.46
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
TMEM97 Q5BJF2 5/20 0.43
SIGMAR1 Q99720 5/20 0.43
LMNA P02545 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
F13A1 P00488 1/20 0.43
TGM2 P21980 1/20 0.43
TGM1 P22735 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17785833 0.94 ALDH1A1 (0.65) ALDH1A1HPNST14CA1CA2
SCHEMBL31258880 0.83 ALDH1A1 (0.56) ALDH1A1HPNST14CA1CA2
SCHEMBL30249936 0.83 ALDH1A1 (0.56) ALDH1A1HPNST14CA1CA2
SCHEMBL21815402 0.81 ALDH1A1 (0.57) ALDH1A1LMNACYP3A4MAPT
SCHEMBL20099653 0.80 KMT2A (0.50) ALDH1A1
SCHEMBL25208191 0.79 ALDH1A1 (0.51) ALDH1A1HPNST14CA1CA2
SCHEMBL16333850 0.78 MEN1 (0.59) ALDH1A1HPNST14CA1CA2
SCHEMBL18824341 0.77 ALDH1A1 (0.62) ALDH1A1LMNACYP3A4MAPT
SCHEMBL1250612 0.76 ALDH1A1 (0.53) ALDH1A1CYP3A4MAPT
SCHEMBL1250614 0.76 ALDH1A1 (0.53) ALDH1A1CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3856737-B1 HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE HOFFMANN LA ROCHE (CH) 2023-05-17 EP disclosed
CN-112752755-A Heterocyclyl compounds for the treatment of autoimmune diseases 豪夫迈·罗氏有限公司 2021-05-04 CN disclosed